In this study, we identified two novel LRP5 mutations in patients with FEVR. Mild reduced bone mineral density (BMD) was also revealed in members with LRP5 mutation in both of the families. We further confirmed that the two mutants failed to induce luciferase reporter activity in response to Norrin in a HEK293 cell line transfected with a luciferase reporter, which implicated the mutants to be pathologic. School of Medicine, China and informed consent was obtained from all the participants. The study adhered to the tenets of the Declaration of Helsinki. Ophthalmic examinations including the fundus photography or ultrasound examination were conducted in all patients with FEVR. Fundus fluorescein angiography (FFA) was performed in parents to confirm the family history. In the 300 normal matched controls, all individuals underwent an eye examination and no signs of eye diseases were observed. The family members in which the LRP5 mutation was detected underwent standard dual-energy X-ray absorptiometry (DEXA) bone scanning to measure BMD using the GE Lunar Prodigy DEXA densitometer. T scores (number of standard deviations from the mean derived from healthy young sex-matched adults) are the usual format for expressing BMD in adults. For children, Z scores (standard deviations from the mean derived from an age, sex, and racially matched population) are generated by imaging the spine.
METHODS

Patients and clinics:
Mutation screening: Peripheral blood was collected in EDTA tubes from patients and parents with FEVR and normal control subjects and was preserved in -20 ˚C prior to use. Genomic DNA was isolated using the salt precipitation method, including lysis, precipitation, wash and resuspension. Genomic DNA was isolated using the salt precipitation method. PCR primers were designed to include flanking Table) . The exons of the four genes were analyzed via the direct sequencing of PCR products. Amplified products were purified using the QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA) and sequenced with forward and reverse primers by the BigDye® Terminator v3.1 Cycle Sequencing Kit (ABI Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Amplified products were purified using the QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA) and sequenced with forward and reverse primers by the BigDye® Terminator v3.1 Cycle Sequencing Kit (ABI Applied Biosystems, Foster City, CA) according to the manufacturer's instructions (After the template and the primers were set, prepare the BigDye premix reactions for 96-Well plate. Then perform the cycle sequencing on the system, purify the extension products and analyze the samples on a sequencer).
Construction of expression plasmids:
The gene encoding wild-type LRP5 (Origene, Rockville, MD) was subcloned in-frame into the pRK5 vector (BD Bioscience, San Jose, CA) using the XbaI and HindIII sites. FZD4 and Norrin cDNAs fused to reporter sequences/genes (generously provided by Dr. Jeremy Nathans) have been described previously [19, 30] . LRP5 mutations were introduced into the wild-type LRP5
cDNA by primer-mediated PCR mutagenesis using the QuikChange® Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA). The recombinant plasmids containing LRP5-pRK-5 fusion constructs were verified by direct DNA sequencing and then amplified and purified for transfection (Tiangen, Biotech, Beijing, China). ) from the unaffected mother had similar luciferase reporter activity compared with the wild type, while the second mutation of Patient 2 (p.T852M), which was not detected in either parent, exhibited a 94.9% reduction. The luciferase intensities of the two combinations (p.A422T and p.Q816P, p.L540P and p.T852M) decreased significantly compared to the wild type, but no significant differences were observed compared with the mere mutation (p.A422T or p.L540P; p>0.05). The mutant p.R570Q (positive control) exhibited a 96% reduction of its wild-type activity, which was similar to the results of a previous report. Asterisks indicate significant differences between the mutant and wild type as judged by the Student two-tailed t test (p<0.05). 
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RESULTS
Clinical evaluation:
The clinical information of the two patients is given below. Patient 1 was a 10-year-old boy who presented with poor vision and nystagmus in both eyes. The visual acuities were 2/200 in his right eye and 20/320 in his left eye, respectively. RetCam examination showed retinal fold of the right eye and dragged disc of the left eye. Both eyes had peripheral non-perfusion areas. The patient has been followed up for 2 years and the retinal folds remained stable ( Figure 1A, B) . His father had a good vision of 20/20 in both eyes, while FFA showed nonperfusion areas of both eyes ( Figure 1C-F) . Patient 2 was a 4-month-old male infant when first referred to our clinics. He was found to have leukocoria of both eyes by the parents. Ophthalmological examinations showed bilateral retinal detachment. The left eye was more severe than the right eye. Lensectomy and vitrectomy were performed in the right eye. The left eye's condition was too severe and it was unlikely to benefit from surgery; thus, it remained untreated. The retina was mostly attached in the right eye during 2 years of follow-up. Visual acuity measurement was difficult in this patient due to his young age. However, the patient was capable of walking without aid at the last follow-up (Figure 2A -E). The mother had normal eyesight, while FFA showed nonperfusion areas, increased ramification, and shunts of the peripheral retinal vessels in both eyes ( Figure 2F-I ).
Neither the patients nor the parents showed any clinical sign of bone abnormality. However, DEXA analysis showed mild reduced BMD in the two patients and the affected father of Patient 1 and the affected mother of Patient 2. In Family 1, the Z score of Patient 1 was −1.8 and the T score of his affected father was also −1.8. In Family 2, the Z score of Patient 1 was −2.0 and the T score of his affected mother was −1. Table 1 . In addition to p.A422T, an additional LRP5 sequence change (c.2447A>C, p.Q816P) from the unaffected mother was detected in Patient 1. Moreover, beyond p.L540P, Patient 2 had an additional LRP5 sequence change (c.2555C>T, p.T852M); this was not detected in either parent, suggesting that it was a new mutation in Patient 2 ( Figure  3) . The two sequence changes also involved evolutionarily conserved residues (Figure 4) .
We also detected novel variants in the untranslated regions (UTRs), specifically a deletion in the 3′ UTR of the FZD4 gene in Family 1,2 and an insertion in the 5′ UTR of the TSPAN12 gene in Family 2 (Table 1) . We searched the 3′ UTR mutation of the FZD4 gene in miRanda and Microcosm and we did not find any site change of miRNA binding. We also searched in TRRD and did not find any binding site of the transcript factor in either the wild-type and the mutant 5′ UTR area of the TSPAN12 gene. No NDP mutations were detected in either family.
Defective luciferase reporter activity mediated by mutant LRP5 protein: Under physiological conditions, a complex of Norrin, FZD4, and LRP5 activates Norrin/β-catenin signaling, which can be demonstrated using a Norrin responsive firefly luciferase reporter. Both of the novel LRP5 mutants displayed a significant reduction of the luciferase reporter activity in STF cells in response to Norrin (87% reduction for p.A422T and 97% reduction for p.L540P). We constructed one previously reported LRP5 mutation (p.R570Q) as a control. It lost 96% of its wild-type activity, which was similar to the results of a previous report ( Figure  5 ) [31] . To further investigate the two additional LRP5 mutations (p.Q816P and p.T852M), we also carried out luciferase assay. The mutation of Q816P had similar luciferase reporter activity compared with the wild type, while the mutation of p.T852M exhibited a significant reduction (94.9%). As for the luciferase activity of the two combinations of mutations (p.A422T and p.Q816P, p.L540P and p.T852M), the intensities decreased significantly compared to the wild type, but no significant differences were noticed compared with the single mutation of p.A422T or p.L540P.
DISCUSSION
In our study, we detected two novel heterozygous LRP5 mutations in two families with FEVR that were not detected in 300 normal individuals. Thus far, 32 different mutations of LRP5 have been reported to relate to FEVR, including five premature stop codons, 25 missense changes, and two changes that affect splicing (Table 2) .
LRP5 encodes single-pass transmembrane receptors that partner with members of the frizzled family of seven-pass transmembrane receptors to bind Wnt proteins or Norrin, forming a functional ligand-receptor complex that activates the canonical Wnt-β-catenin pathway or Norrin/β-catenin pathway [23] [24] [25] . LRP5 consists of four extracellular domains, each of which is composed of six segments. Those segments form a β-propeller structure that is followed by an epidermal growth factor (EGF)-like domain. Five of those segments are YWTD LDL-class B repeats, whereas the sixth does not contain the required YWTD motif to be recognized as a LDL-class B repeat. The first two propeller domains were suggested to be important for interaction with the Wnt or Norrin/Frizzled complex [32] . Both of the novel missense mutations (p.A422T and p.L540P) are located in the second "β-propeller" domain of the protein, at an evolutionarily highly conserved position. Functional analysis was performed using luciferase reporter assay. The significant defective Norrin-β-catenin signaling with the p.A422T and p.L540P mutation in LRP5 underlies FEVR. This is consistent with the previously reported mutation p.R570Q, which was also located in the second β-propeller domain [31] . The difference of the decreased intensity of the two mutants (87% of p.A422T versus 97% of p.L540P) may due to the location and importance of this amino acid in the β-propeller domain.
FEVR can exhibit variable phenotypes among patients from the same family, or even between the two eyes of one individual [1] . In our study, the two patients manifested more severe symptoms than the affected father or mother. Considering our gene screening results, besides p.A422T, an additional LRP5 mutation of p.Q816P from his unaffected mother was detected in Patient 1 and Patient 2 had an additional new LRP5 mutation of p.T852M that was not found in either of his parents. Previously, Qin et al. [13] reported a case with combined mutations of LRP5 (p.F617C and p.T535M), which were from the affected mother and the unaffected father, respectively. The affected mother was completely asymptomatic but had retinal avascularization with tortuosity of the retinal vessels in her right eye. She also had mildly reduced bone density. The father showed neither retinal change nor reduced bone mass. Kondo et al. [33] reported a FEVR patient exhibited a double sequence change in FZD4 (p.G488D from the affected mother and p.H69Y from the unaffected father). The proband with both p.G488D and p.H69Y presented with a more severe phenotype than the mother who carried a single p.G488D mutation. Our cases are similar to these reports. The two sequence changes (p.Q816P and p.T852M) were located in the third β-propeller domain of the protein, which is less important than the first two β-propeller domains. The additional LRP5 mutation of Q816P in Patient 1 had similar luciferase reporter activity compared with the wild type, which implies that the mutation (p.Q816P) may not be pathogenic. However, the mutation of p.T852M in LRP5 showed a significant decrease in luciferase activity. This implies the second new mutation of Patient 2 (p.T852M) may be pathogenic. Previously, Qin et al. [34] reported a combination of R444C in LRP5 and R417Q in FZD4 displayed a sharp decline compared with the single mutation. Our results showed no significant differences between the single mutation and the combination of the mutations. However, the exact pathogenicity of the sequence changes and whether the additional combination of the mutations will lead to the severe phenotype needs further study.
In addition to causing FEVR, defects in LRP5 have also been associated with bone abnormalities [13, 26, 28, 29, 31, 35, 36] , which were also found in our patients. Although they showed no signs of reduced bone mass clinically, the reduced BMD suggested osteopenia of these patients and their affected parents. This result added further evidence supporting the claim that bone density abnormalities are a consequence of LRP5 mutations. Therefore, we should inquire into the history of bone defects in those patients who were diagnosed as FEVR. BMD examination should be performed if possible, especially for those in which LRP5 mutation is detected.
In conclusion, two novel heterozygous mutations (p.A422T and p.L540P) in LRP5 were verified in two families, and further confirmed by luciferase activity assay. The results provide additional evidence that mutations in LRP5 cause FEVR. The complexity of genotype-phenotype correlation needs to be further studied.
APPENDIX 1. PRIMERS USED FOR PCR AMPLIFICATION AND SEQUENCING OF FZD4, NDP, TSPAN12, AND LRP5.
To access the data, click or select the words "Appendix 1."
